Implementing the World Health Organization Guidelines for Rheumatic Heart Disease in Highly Endemic Settings: Balancing Evidence with Reality

在风湿性心脏病高发地区实施世界卫生组织风湿性心脏病指南:平衡证据与现实

阅读:2

Abstract

In 2024, the World Health Organization (WHO) released rheumatic heart disease (RHD) guidelines; however, implementation in highly endemic countries remains challenging. The severe nature of RHD in such areas necessitates adopting pragmatic approaches to improve diagnostic yield. The WHO continues to recommend the Jones Criteria for the diagnosis of acute rheumatic fever, even though these criteria have been shown to miss up to 10% of cases. Using simplified clinical criteria is expected to have better sensitivity at the level of frontline health workers. The WHO recommendation to use handheld echocardiography for diagnosis of RHD is a crucial asset for secondary and tertiary prevention of RHD; however, implementation of this strategy might be hampered by limited availability and the need for expert training. While benzathine penicillin G remains the cornerstone of RHD treatment, as recommended by the WHO, persistent issues related to its availability and proper administration techniques need to be addressed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。